[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-urinary-track-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-urinary-track-symptoms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,77,101,127,152,180,215,242,269],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100637887","phase-4-silodosin-for-urinary-symptoms-in-female-patients-with-multiple-sclerosis-100637887",false,"NCT07614321","Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis","Is Silodosin Effective for Treating Lower Urinary Tract Symptoms in Female Patients With Multiple Sclerosis? A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female patients with a diagnosis of multiple sclerosis\n2. Age \\> 18\n3. Moderate to severe lower urinary tract symptoms as defined by an AUASS score \\> 8\n4. No UTI\n\nExclusion Criteria:\n\n1. Treatment with alpha-blocker, B3 agonist, or anticholinergic medication within the last 6 weeks\n2. Treatment with sacral neuromodulation, bladder Botox, or posterior tibial nerve stimulation within the last 9 months\n3. Renal impairment with CrCl \\\u003C 30\n4. PVR \\> 300\n5. Diagnosed orthostatic hypotension\n6. Pregnancy or breastfeeding\n7. Severe liver impairment (Child-Pugh class C)\n8. Current symptomatic kidney stones\n9. Recent MS relapse within the last 3 months\n10. Recent treatment with steroids in the last 3 months (this does not include one-time pre-treatment with steroids for administration of immunologic drug)","FEMALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are:\n\nDoes silodosin improve lower urinary tract symptoms based on questionnaires? Does silodosin change Uroflowmetry parameters in female patients with MS? Researchers will compare silodosin to a placebo (a look-alike substance that contains no drug) to see if silodosin works to treat LUTS in female patients with MS.\n\nParticipants will:\n\nTake silodosin or a placebo every day for 8 weeks Visit the clinic before initiating the medication and after 8 weeks of taking the medication for questionnaires and tests",[26,27],"Multiple Sclerosis","Lower Urinary Track Symptoms","RECRUITING","2026-05-26",{"date":31,"type":32},"2026-05-29","ACTUAL",{"date":34,"type":20},"2026-04",{"date":36,"type":20},"2028-04",{"name":38,"class":39},"Atlantic Health System","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":40},"100636290","low-energy-shock-wave-therapy-for-overactive-bladder-in-women-with-metabolic-syndrome-100636290","NCT07563764","Low-Energy Shock Wave Therapy for Overactive Bladder in Women With Metabolic Syndrome","A Randomized, Double-Blind, Sham-Controlled Trial of Low-Energy Extracorporeal Shock Wave Therapy for Overactive Bladder in Women With Metabolic Syndrome","Inclusion:\n\n* Female participants aged 20 to 75 years\n* Diagnosed with overactive bladder (OAB), defined as urinary frequency (≥8 times\u002Fday), nocturia (≥2 times\u002Fnight), and urgency (≥2 episodes\u002Fweek) for at least 3 months\n* Diagnosed with metabolic syndrome, defined by the presence of at least three of the following criteria:\n* Waist circumference ≥80 cm\n* Blood pressure ≥130\u002F85 mmHg or receiving antihypertensive treatment\n* Fasting glucose ≥100 mg\u002FdL or receiving treatment for diabetes\n* Triglycerides ≥150 mg\u002FdL or receiving lipid-lowering treatment\n* High-density lipoprotein cholesterol \\\u003C50 mg\u002FdL\n* No pharmacological or injection treatment for OAB within 3 months prior to enrollment\n* Able to understand and comply with study procedures and questionnaires\n* Willing to provide informed consent\n\nExclusion:\n\n* History of kidney stones or bladder stones\n* Urinary tract infection within 3 months prior to enrollment or recurrent urinary tract infections (≥3 episodes)\n* Lower urinary tract surgery within 6 months prior to enrollment\n* Known or suspected malignancy of the urinary tract\n* Significant bladder outlet obstruction\n* Severe coagulopathy, liver failure, or renal failure\n* Prior pelvic malignancy or pelvic radiation therapy\n* Intravesical injection or electrical stimulation therapy within the past year\n* Substance abuse (drug or alcohol) within the past year\n* Chronic pelvic pain due to other causes\n* Inability to complete study questionnaires or procedures","20 Years","75 Years",{"count":19,"type":20},[52],"NA","Overactive bladder (OAB) is a common condition that causes urinary urgency, frequent urination, and nocturia, which can significantly affect quality of life. Women with metabolic syndrome may have a higher risk of OAB due to vascular and metabolic abnormalities.\n\nThis study aims to evaluate the effectiveness and safety of low-energy extracorporeal shock wave therapy (LiESWT), a non-invasive treatment, in women with metabolic syndrome-associated OAB. Participants will be randomly assigned to receive either active LiESWT treatment or a sham (inactive) procedure.\n\nSymptoms and treatment outcomes will be assessed using validated questionnaires, including the Overactive Bladder Symptom Score (OABSS), International Consultation on Incontinence Questionnaire (ICIQ-SF), Urinary Distress Inventory (UDI-6), and Incontinence Impact Questionnaire (IIQ-7), as well as a voiding diary and uroflow measurements.\n\nThe results of this study may help determine whether LiESWT is an effective treatment option for improving OAB symptoms in this patient population.",[55,27,56,57,58],"Bladder","Metabolic Syndrome","Urgency-Frequency","Bladder, Overactive",[60,61,62,63,64,65,66,67],"Low-energy extracorporeal shock wave therapy","LiESWT","Overactive bladder","Metabolic syndrome","Urinary urgency","Urinary frequency","Nocturia","Randomized controlled trial","2026-04-30",{"date":70,"type":32},"2026-05-04",{"date":72,"type":32},"2025-02-10",{"date":74,"type":20},"2026-06-30",{"name":76,"class":39},"KMUHIRB-F(I)-20230051",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":4,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100636184","outcome-and-patient-experiences-after-transurethral-resection-and-bipolar-enucleation-of-the-prostate---a-multi-center-randomized-controlled-trial-100636184","NCT07562386","Outcome and Patient Experiences After Transurethral Resection and Bipolar Enucleation of the Prostate - a Multi-center, Randomized Controlled Trial.","Inclusion Criteria:\n\nMen with prostate sizes between 30mL and 80mL on ultrasound, referred to BPH surgery, detrusor pressure ≥ 20 cmH2O on urodynamic tests, valid informed consent.\n\nExclusion Criteria:\n\nPrevious surgery for BPH, men aged above 80 years old, severe comorbidity (not suitable for surgery), cognitive impairment, prostate cancer (palliative surgery), prior pelvic radiation therapy, anticoagulation\u002Fantiplatelet therapy can't be stopped.","MALE","80 Years",{"count":86,"type":20},120,[52],"In this randomized controlled trial, we will evaluate if bipolar enucleation of the prostate (BEEP) is associated with better urinary voiding outcome than transurethral resection (TURP) in men with enlarged prostate referred to surgery. In addition we will investigate the association between symptom relief and the amount of removed tissue and if patients experience differ between the two methods. Finally, we will assess cost-effectiveness of BEEP compared to TURP. The main outcome for comparison of the two surgical methods is International Prostate Symptom Score (IPSS) assessed at 12-month follow-up. The primary outcome to assess patient experience is measured with the questionnaire Nordic Patients Experience Questionnaire (NORPEQ). Cost-effectiveness will be measured with incremental cost-effectiveness ratio (ICER).",[27,90],"Benign Prostate Obstruction (BPO)","2026-04-24",{"date":93,"type":32},"2026-05-01",{"date":95,"type":32},"2025-09-25",{"date":97,"type":20},"2028-12",{"name":99,"class":39},"Sykehuset Innlandet HF",2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":108,"minAge":48,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100585703","e-sense-normal-values-of-urodynamic-pressures-using-e-sense-catheters-100585703","NCT06905808","e-Sense® Normal Values of Urodynamic Pressures Using e-Sense® Catheters","ESNS-01","Inclusion Criteria:\n\n* Subjects medically indicated for Urodynamic procedure between ages 20-35 or \\> 50 years old (equally split male and female)\n* Due to aging and giving birth significantly affecting the urethra:\n* Female subjects 20-35 should be nulliparous.\n* Female subjects \\> 50 years old should have given birth to at least one child vaginally. Further caesarian births would not mean exclusion from the study.\n* Subjects with range of BMI values\n* Subject provides written authorization and\u002For consent per institution or geographical requirements\n\nExclusion Criteria:\n\n* Subjects with cognitive or psychiatric conditions that interfere with or precludes direct and accurate communication regarding the study, giving informed consent\n* Any anal \u002F rectal symptoms and\u002For surgery\n* Pregnant women\n* Subjects with active untreated bladder infections (not including patients with asymptomatic bacteruria)\n* Subjects having greater than 300 mL post void residual on the clinic visit uroflowmetry test","ALL",{"count":110,"type":20},40,"OBSERVATIONAL","In this post-market observational study, subjects referred to urodynamic testing will be approached to enroll in a clinical study to define the normal range of pressure values utilizing e-Sense® catheters. Urodynamic test results using the study devices will be provided back to the study sponsor for test interpretation and to publish. The urodynamic information collected using the study devices will be used in the UDS test interpretation for each subject enrolled, unless there is a reason to believe the test should be repeated (i.e. inconclusive results).",[27,114],"Urodynamic Exam",[116,27],"Urodynamic","2026-04-23",{"date":119,"type":32},"2026-04-29",{"date":121,"type":32},"2025-08-15",{"date":123,"type":20},"2026-12",{"name":125,"class":126},"Laborie Medical Technologies Inc.","INDUSTRY",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":108,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100631949","turkish-version-of-the-neurogenic-bladder-symptom-score-short-form-100631949","NCT07507331","Turkish Version of the Neurogenic Bladder Symptom Score Short Form","Turkish Version of the Neurogenic Bladder Symptom Score Short Form: Cross-Cultural Adaptation and Validation-Reliability Study","Inclusion Criteria:\n\n* Being ≥18 years old\n\n  * Having a diagnosis of Spinal Cord Injury (SCI) or Multiple Sclerosis (MS) and neurogenic lower urinary tract dysfunction\n  * Being able to read and understand Turkish and have the cognitive ability to independently complete questionnaires\n  * Can be included with any bladder management method (spontaneous voiding, CIC, permanent catheter, condom catheter, reconstruction\u002Fdiversion etc.)\n  * Volunteering and signing informed consent\n\nExclusion Criteria:\n\n* Having an active urinary tract infection (UTI)\n* Having undergone urological surgery in the last month\n* Reporting changes in bladder\u002Furinary function between the first and second applications (surgery, UTI, change in bladder medication)\n* Having a significant recent change in general health status\n* Having a spinal cord injury (SCI) in the spinal shock phase\n* Having experienced a relapse of Multiple Sclerosis (MS) within the last 3 months.",{"count":86,"type":20},"This observational study aims to evaluate the cross-cultural adaptation and psychometric properties of the Turkish version of the Neurogenic Bladder Symptom Score Short Form (NBSS-SF) in adults with spinal cord injury or multiple sclerosis who have neurogenic lower urinary tract dysfunction. Neurogenic bladder symptoms, such as urinary incontinence, urgency, and difficulties with urine storage or emptying, may negatively affect daily functioning and quality of life. In this study, the validity and reliability of the Turkish NBSS-SF will be examined, and convergent validity will be assessed through its relationship with the King's Health Questionnaire (KHQ) and the Short Form-12 (SF-12). In eligible participants, the scale will be administered again after 7 to 14 days. The aim of the study is to provide a valid and reliable Turkish patient-reported outcome measure for use in clinical practice and research.",[137,138,26,27],"Neurogenic Bladder Disorder","Spinal Cord Injury",[140,141,138,26],"Neurogenic Bladder","Neurogenic Bladder Symptom Score- Short Form Validation","NOT_YET_RECRUITING","2026-04-07",{"date":145,"type":32},"2026-04-13",{"date":147,"type":20},"2026-03-27",{"date":149,"type":20},"2026-05",{"name":151,"class":39},"Gaziantep Islam Science and Technology University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":40},"100588649","phase-2-new-treatment-strategies-and-epigenetic-biomarker-for-management-of-benign-prostatic-hyperplasia-100588649","NCT06944145","New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia","A Phase 2b Randomized, Single-Center, Double Blind, Placebo Controlled, 2-Arm Study to Investigate Orally Administered Combination Therapies (5-alpha Reductase Inhibitor + Raloxifene) Compared With Monotherapy (5-alpha Reductase Inhibitor + Placebo) in Adult Patients With Benign Prostatic Hyperplasia (BPH)","Inclusion criteria\n\n1. ≥18 yrs old on the day of study consent;\n2. Finasteride has been recommended for treatment of BPH by a physician;\n3. PSA \\\u003C20ng\u002Fml within the last six months;\n4. Willingness to maintain any current genitourinary medications (e.g., beta agonists, alpha blockers, anticholinergics);\n5. Patient is able and willing to provide written informed consent.\n\nExclusion criteria\n\n1. Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis;\n2. Previous diagnosis with any prostatic malignancy or precancerous lesions (atypical glandular foci);\n3. History of pelvic radiation;\n4. Actively receiving intravesical therapy for bladder cancer;\n5. Received treatment with any demethylating medications (azacitidine, decitabine, zebularine, guadecitabine, hydralazine);\n6. Current use of warfarin;\n7. Prior treatment with 5ARI medications (e.g., Finasteride or Dutasteride) in the last year;\n8. Diagnosed with diabetes mellitus;\n9. Diagnosed with any neurodegenerative diseases;\n10. History of allergic reaction to any intravenous (IV) iron replacement products;\n11. Currently taking cholestyramine medication;\n12. Contraindications to MRI examination, which may include:\n\n    * Cardiac pacemaker\n    * Intracranial clips, metal implants, or external clips within 10mm of the head\n    * Previous metal injury in the eye or occupation risk to ferrous metal in the eye (e.g. metalworker)\n    * Claustrophobia that cannot be managed with benzodiazepine",{"count":160,"type":20},242,[162],"PHASE2","SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.",[165,27],"BPH (Benign Prostatic Hyperplasia)",[167,168,169,170],"BPH","SRD5A2","Finasteride","LUTS","2026-03-19",{"date":173,"type":32},"2026-03-23",{"date":175,"type":32},"2025-12-03",{"date":177,"type":20},"2030-08-31",{"name":179,"class":39},"Beth Israel Deaconess Medical Center",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100580196","online-adaptive-stereotactic-body-radiotherapy-for-localized-prostate-cancer-x-smile-100580196","NCT06834152","Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer (X-SMILE)","Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer in Patients With Lower Urinary Tract Symptoms and\u002For Prostate Hyperplasia (X-SMILE)","X-SMILE","Inclusion Criteria:\n\n* histologically confirmed localized prostate cancer\n* planned treatment is SBRT according to standard of care and consists of definitive CT or MRI online adaptive SBRT of the prostate according to the PACE trial which includes a total dose to clinical target volume 1 (CTV1, i.e. prostate and proximal 1 cm of the seminal vesicle) of 40.0 Gy in 5 weekly fractions (single dose of 8.0 Gy) and total dose to planning target volume 1 (PTV1) of 37.5 Gy in 5 weekly fractions (single dose of 7.5 Gy) with a compromise for bowel sparing allowed. For patients with unfavorable intermediate to very high-risk disease (according to NCCN guidelines) a total dose to the planning target volume 2 (PTV2, i.e. proximal 1-2 cm of the seminal vesicle) of 32.5 Gy in 5 weekly fractions (single dose of 6.5 Gy) will be delivered.\n* intermediate to (very) high risk localized prostate cancer (≤ cT3a and Gleason score ≤ 9 and\u002For PSA ≤ 20 ng\u002Fml)\n* prostate volume \\> 60 cc and\u002For IPSS \\> 12;\n\nExclusion Criteria:\n\n* Very high risk localized prostate cancer with indication for ADT and ARPI (i.e. Gleason ≥ 8 and cT3a)\n* Involvement of seminal vesicles (cT3b)\n* Contraindications against definitive CT or MRI-adaptive radiotherapy of the prostate, e.g. inflammatory bowel disease (IBD); previous radiotherapy in the pelvis, previous local radiotherapy of the prostate, contraindication for MRI or CT;\n* Patients with severe genitourinary symptoms (e.g. recent urinary retention ≥ grade 3 according CTCAE v.5.0);\n* Lymph node metastases or distant metastases (i.e. no localised prostate cancer);\n* Participation in a clinical trial which might influence the results of this project.",{"count":189,"type":20},75,"The aim of this phase II international multicenter study is to evaluate the safety, feasibility, and efficacy of CT or MRI-adaptive SBRT, delivered in five weekly fractions, in patients with newly diagnosed localized prostate cancer who have lower urinary tract symptoms and\u002For prostatic hyperplasia.",[192,193,194,27],"Localized Prostate Carcinoma","Prostate Cancer (Adenocarcinoma)","Prostate Hyperplasia",[196,197,198,199,200,201,202,203,204],"radiotherapy","SBRT","MRI","CT","stereotactic radiotherapy","localized prostate cancer","lower urinary tract symptoms","prostate hyperplasia","prostate cancer","2026-02-04",{"date":207,"type":32},"2026-02-09",{"date":209,"type":32},"2024-03-01",{"date":211,"type":20},"2031-06-30",{"name":213,"class":39},"University of Zurich",3,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":40},"100622000","intradetrusor-onabotulinumtoxin-a-botox-at-the-time-of-transurethral-resection-of-the-prostate-or-transurethral-waterjet-ablation-of-the-prostate-for-mixed-lower-urinary-tract-symptoms-100622000","NCT07377929","Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms","Inclusion Criteria:\n\n1. Male \\>= 18 years of age and being scheduled to undergo TURP or Aquablation and Botox procedure.\n2. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\n   Exclusion Criteria:\n3. Non-English speaking\n4. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n5. History of receiving Botox in the bladder, within the previous 12 months.",{"count":222,"type":20},20,"Patients with longstanding obstructive lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) can also develop symptoms of overactive bladder syndrome (OAB). Transurethral resection of the prostate (TURP) and Transurethral Waterjet Ablation of the Prostate (Aquablation) are amongst the gold standard surgical treatments for BPH. However, in the immediate post-operative period, TURP and Aquablation can also include OAB-like symptoms, including urinary frequency and urgency. For men with baseline OAB symptoms, this initial worsening of symptoms can be distressing.\n\nBotox is an FDA approved medication with on-label indications to treat overactive bladder.\n\nThe purpose of this study is to evaluate the outcomes of men who have Botox concurrent with their TURP or Aquablation.",[225,27],"Benign Prostatic Hypertrophy (BPH)",[227,228,229,230,231,232],"lower urinary tract symptoms (LUTS)","benign prostatic hypertrophy (BPH)","overactive bladder syndrome (OAB)","Transurethral resection of the prostate (TURP)","Transurethral Waterjet Ablation of the Prostate (Aquablation)","Botox","2026-01-22",{"date":235,"type":32},"2026-01-30",{"date":237,"type":20},"2026-01-19",{"date":239,"type":20},"2027-05-01",{"name":241,"class":39},"Benaroya Research Institute",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":40},"100575262","evaluation-of-the-optilume-bph-catheter-system-and-the-rezum-water-vapor-therapy-in-treating-benign-prostatic-hyperplasia-100575262","NCT06769997","Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia","The Optizum Study: A Randomized, Blinded Single Center Study Evaluating the Optilume BPH Catheter System and the Rezum Water Vapor Therapy for the Treatment of Benign Prostatic Hyperplasia","OptiZum","Inclusion Criteria:\n\n* Male subject with symptomatic BPH.\n* Prostate size 30-100g.\n* Able to complete the study protocol.\n\nExclusion Criteria:\n\n* Unable or unwilling to sign the Informed Consent Form (ICF) and\u002For comply with follow-up requirements\n* Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate\n* Any prior minimally invasive intervention (e.g., TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate\n* Confirmed or suspected malignancy of prostate or bladder\n* Active urinary tract infection (UTI) confirmed by culture\n* History of overt urinary incontinence requiring use of pads NOTE: Pad usage for post-micturition dribble is acceptable\n* Presence of confounding diagnoses impacting lower urinary tract symptoms or bladder function (e.g., urethral strictures, bladder neck contracture, neurogenic bladder, detrusor instability, bladder stones, etc.)\n* History of chronic urinary retention (e.g., PVR ≥300mL on two separate occasions, or catheter dependent drainage)\n* Anatomy (e.g., presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System\n* Significant obstruction from median lobe (investigator opinion)\n* Disease or other health condition that is not suitable for this study",{"count":251,"type":20},100,[52],"Lower urinary symptoms (LUTS) affect older men and their frequency and severity increase with age. According to Berry et al., the histological diagnosis of benign prostatic hyperplasia (BPH) increases from 25% in the group age between 40 to 49 years to 80% in the group age between 70 to 79 years (1). However, this hyperplasia can lead to a bladder outlet obstruction (BOO) secondary to benign prostatic enlargement (BPE), causing storage and voiding symptoms, associated with a considerable impairment of the quality of life (2).\n\nSurgical therapy of BPH has continuously evolved in recent years. The current gold standard for the endoscopic treatment of BPH is the transurethral resection of the prostate (TURP). Other innovative techniques were developed including Urolift, transurethral laser enucleation (holmium, thulium) and Aquablation therapy. One of the latest technologies for the management of BPH are Optilume BPH Catheter System (Optilume®, Urotronic Inc, Minneapolis, USA) and Rezum Water Vapor Therapy (Rezum System, Bostocn Scientific, Marlborough, MA).\n\nThe purpose of the present study is to compare between patient experience, symptom relief and functional improvement when using the Optilume BPH Catheter System (Optilume®, Urotronic Inc, Minneapolis, USA) and Rezum Water Vapor Therapy (Rezum System, Boston Scientific, Marlborough, MA).",[255,27],"Benign Prostatic Hyperplasia (BPH)",[257,27,167,170,258,259],"Benign Prostatic Hyperplasia","Optilume","Rezum","2025-07-14",{"date":262,"type":32},"2025-07-17",{"date":264,"type":32},"2025-05-09",{"date":266,"type":20},"2027-01",{"name":268,"class":39},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":83,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":21,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":40},"100565572","effects-of-lumbopelvic-stabilization-based-physiotherapy-and-rehabilitation-training-in-duchenne-muscular-dystrophy-100565572","NCT06643923","Effects of Lumbopelvic Stabilization-based Physiotherapy and Rehabilitation Training in Duchenne Muscular Dystrophy","Investigation of the Effects of Lumbopelvic Stabilization-based Physiotherapy and Rehabilitation Training on Lower Urinary Tract Symptoms in Children With Duchenne Muscular Dystrophy and Lower Urinary Tract Dysfunction","Inclusion Criteria:\n\n* Having been diagnosed with DMD by a specialist physician,\n* Having received a score of 8.5 or higher on the Voiding Disorders Symptom Score (VMSS),\n* Being between the ages of 8-12,\n* Continuing ambulation (Vignos Scale Stage 1-4),\n* Volunteering to participate in the study by parents and reading and signing the informed consent form.\n\nExclusion Criteria:\n\n* Having another neuromuscular disease diagnosed other than DMD and\u002For accompanying DMD,\n* Having family and\u002For child having cooperation problems in completing the evaluations for any reason,\n* Lack of internet infrastructure or technical infrastructure that may cause difficulty in continuing distance education\u002Ffollow-up,\n* Having difficulty in understanding and speaking the Turkish language.","8 Years","12 Years",{"count":279,"type":20},34,[52],"This study aims to examine the effectiveness of supervised lumbopelvic stabilization in relation to factors associated with lower urinary tract symptoms in children diagnosed with Duchenne Muscular Dystrophy (DMD) who have lower urinary tract dysfunction. Children aged between 8 and 12 years, at stages 1-4 according to the Vignos scale, and who have a score of 8.5 or higher on the Dysfunctional Voiding Symptom Score (DVSS), will be included in the study. Demographic information will be collected through a general assessment form, while lower urinary tract symptoms will be assessed using the DVSS, a researcher-developed evaluation form, and a three-day bladder diary. Bowel symptoms will be evaluated using the Rome IV criteria and a seven-day bowel diary. Physical performance will be assessed via the Timed Up and Go Test and Gower's Test, muscle strength using the microFET2 hand dynamometer, lumbar lordosis angle with a Bubble inclinometer, participation in daily living activities via the Barthel Index, and perceived well-being of both the child and the parent will be assessed using the Faces Rating Scale. Participants will be randomly assigned to two groups (Treatment and Active Control) using a block randomization method. In the Active Control group, children will receive only urotherapy education. In the Treatment group, children will receive supervised, online, lumbopelvic exercise-based physiotherapy and rehabilitation sessions, in addition to urotherapy, conducted by a physiotherapist. The sessions will last eight weeks, with a total of 24 sessions. At the end of the eight-week period, both groups will be re-evaluated using the same assessment methods. Intra-group and inter-group comparisons will be completed using appropriate analytical methods.",[283,27],"Duchenne Muscular Dystrophy (DMD)",[285,202,286,287,288],"Duchenne muscular dystrophy","urotherapy","lumbopelvic exercise","physiotherapy","2024-10-15",{"date":291,"type":32},"2024-10-16",{"date":293,"type":20},"2024-12-01",{"date":295,"type":20},"2026-12-01",{"name":297,"class":298},"Lokman Hekim University","OTHER_GOV"]